Amine Majdi

Dr. Amine Majdi

Inserm, Paris, Île-de-France, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
AMAmine Majdi
Amine Majdi
LALynda Aoudjehane
Lynda Aoudjehane
VRVlad Ratziu
Vlad Ratziu
TITawhidul Islam
Tawhidul Islam
MAMarta B. Afonso
Marta B. Afonso
JGJérémie Gautheron
Jérémie Gautheron

24 December 2020 in Gut
Verified
Journal Article
Open access
PDF file
MAMarta B. Afonso
Marta B. Afonso
PRPedro M Rodrigues
Pedro M Rodrigues
MMMiguel Mateus-Pinheiro
Miguel Mateus-Pinheiro
ASAndré L Simão
André L Simão
MGMaria M Gaspar
Maria M Gaspar
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Objective: Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD. Design: RIPK3 levels were evaluated in two large independent cohorts of patients with biopsy proven NAFLD diagnosis and correlated with clinical and biochemical parameters. Wild-type (WT) or Ripk3 -deficient ( Ripk3 −/− ) mice were fed a choline-deficient L-amino acid-defined diet (CDAA) or an isocaloric control diet for 32 and 66 weeks. Results: RIPK3 increased in patients with non-alcoholic steatohepatitis (NASH) in both cohorts, correlating with hepatic inflammation and fibrosis. Accordingly, Ripk3 deficiency ameliorated CDAA-induced inflammation and fibrosis in mice at both 32 and 66 weeks. WT mice on the CDAA diet for 66 weeks developed preneoplastic nodules and displayed increased hepatocellular proliferation, which were reduced in Ripk3 −/− mice. Furthermore, Ripk 3 deficiency hampered tumourigenesis. Intriguingly, Ripk3 −/− mice displayed increased body weight gain, while lipidomics showed that deletion of Ripk3 shifted hepatic lipid profiles. Peroxisome proliferator-activated receptor γ (PPARγ) was increased in Ripk3 −/− mice and negatively correlated with hepatic RIPK3 in patients with NAFLD. Mechanistic studies established a functional link between RIPK3 and PPARγ in controlling fat deposition and fibrosis. Conclusion: Hepatic RIPK3 correlates with NAFLD severity in humans and mice, playing a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis. Targeting RIPK3 and its intricate signalling arises as a novel promising approach to treat NASH and arrest disease progression.

10 August 2020 in Biologie Aujourd'hui
Verified
Journal Article
Closed access
PDF file
JMJulie Magusto
Julie Magusto
AMAmine Majdi
Amine Majdi
JGJérémie Gautheron
Jérémie Gautheron
La mort hépatocellulaire chronique et l’inflammation qui en résulte sont des évènements clés dans la progression de la stéatose hépatique non alcoolique (NAFL) vers la stéatohépatite non alcoolique (NASH). La NASH est un état sévère de la maladie qui est associé au développement de la fibrose et qui peut à terme évoluer vers la cirrhose et le cancer du foie. L’apoptose a initialement été étudiée comme cible potentielle pour réduire la mort des hépatocytes dans la NASH. Cependant, des études récentes suggèrent que l’inhibition des caspases est inefficace pour traiter les patients atteints de NASH et pourrait même aggraver la maladie en redirigeant les hépatocytes vers d’autres voies de mort cellulaire. De nouvelles formes de mort cellulaire dites lytiques ont récemment été identifiées et induisent de fortes réponses inflammatoires causées par la perméabilisation des membranes cellulaires. Le contrôle de ces voies de mort lytiques offre par conséquent de nouvelles opportunités thérapeutiques pour traiter la NASH. Cette revue résume les mécanismes moléculaires déclenchant l’apoptose et les voies de mort lytiques, parmi lesquelles la nécroptose, la pyroptose et la ferroptose, et discute de leur pertinence dans la NASH.